| Register
| Log out
Submit An Article

fiona wood

Latest Articles

  • A step closer towards scarless wound healing: Pharmaxis drug through Phase 1 trial

    A step closer towards scarless wound healing: Pharmaxis drug through Phase 1 trial

    Whilst key opinion leaders worldwide are following the Pharmaxis (ASX: PXS) story, Professor Fiona Wood has become an integral part of it.  Following the news out of Rochester University that their myelofibrosis drug, PXS-5505, has a potential significant disease modifying role in other cancers comes another key announcement for the company, this time regarding theirRead More
    Public
  • Spray-on skin revenue exceeds initial forecasts

    Spray-on skin revenue exceeds initial forecasts

    The inventors of “spray-on skin”, Avita Medical (ASX: AVH) have today released their financial results for the fiscal fourth quarter with the Company reporting strong revenue. The Company was founded to develop and commercialise the RECELL “spray-on skin” product, invented in Perth by Professor Fiona Wood. Professor Wood is a world renowned surgeon and researcher

    Read More
    Public
  • Karst backs Aussie small cap following hugely successful pharma strategy

    Karst backs Aussie small cap following hugely successful pharma strategy

    Leading fund manager Karst Peak Capital has secured a significant interest in a little-known Aussie pharmaceuticals research company, following the significant success they experienced with a large holding of Avita Medical. Originally based in Hong Kong but now also with an office in Sydney, Karst’s investment focus includes the healthcare, biotech and pharmaceuticals industry which

    Read More
    Public
  • Pharmaxis targeting scar-free recovery from burns with world-first trials

    Pharmaxis targeting scar-free recovery from burns with world-first trials

    One of the world’s most respected surgeons in the field of burns and trauma recovery will lead world-first clinical trials aiming to stop scars forming, particularly after burn injuries, utilising the latest discovery by biopharmaceuticals company Pharmaxis (ASX: PXS).  The discovery, known as PXS-6302 has shown promising pre‐clinical results in inhibiting the enzymes that play

    Read More
    Public

Login or register for free to access unlimited reading

Register Now!

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.